Related Experiment Video
Updated: May 28, 2026
14:51
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
Managing resistance in chronic myeloid leukemia
Sameek Roychowdhury1, Moshe Talpaz
1Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI 48109, USA.
Blood Reviews
|October 11, 2011
Summary
Chronic myeloid leukemia (CML) treatment has advanced with targeted therapies like imatinib. However, resistance necessitates exploring new agents for patients with CML.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm.
- Advances in targeted therapy, particularly imatinib, have transformed CML treatment.
- A significant portion of CML patients require alternative therapies due to resistance or intolerance.
Purpose of the Study:
- To review mechanisms of tyrosine kinase inhibitor (TKI) resistance in CML.
- To discuss novel therapeutic targets and agents for TKI-resistant CML.
- To highlight CML as a model for understanding drug resistance in cancer therapy.
Main Methods:
- Literature review of CML treatment and resistance mechanisms.
- Analysis of current research on novel targets and agents for CML.
- Discussion of clinical implications for managing TKI-resistant CML.
Main Results:
- Imatinib therapy offers durable responses but resistance remains a challenge for many CML patients.
- Mechanisms of primary and secondary resistance to TKIs are complex.
- Up to one-third of CML patients may require alternative treatment strategies.
Conclusions:
- CML treatment has evolved significantly, but resistance necessitates ongoing research.
- Novel therapeutic approaches are crucial for patients with advanced or resistant CML.
- Understanding resistance mechanisms is key to developing more effective CML therapies.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:40Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:30Chronic Obstructive Pulmonary Disease-V: Nursing Management
Nursing management of Chronic Obstructive Pulmonary Disease (COPD) is crucial for providing thorough care and support to patients. Nurses play an integral role in this process through detailed assessment, careful planning, targeted interventions, and ongoing evaluation. Here's an overview of the critical steps in nursing management for COPD.
Assessment
Assessment